{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
ISOMAZOLE is a cardiovascular agent with both inotropic and vasodilator activities. It acts primarily as a phosphodiesterase inhibitor.
Class (Stereo):
CHEMICAL (RACEMIC)
Pamatolol is a beta-Adrenergic receptor antagonist was studied as an Antiarrhythmic agent. The phase I clinical trial has shown that the drug was relatively cardioselective in man. Information about the further development of this drug is not available.
Status:
Investigational
Source:
INN:clofenetamine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Clofenetamine is a haloxanthine antihistamine compound discovered by Searle & Co in the 1940s.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Pargeverine (also known as a propinox) is an antispasmodic drug that was studied for the treatment of disorders of the gastrointestinal tract, the uterus, and the gallbladder. Pargeverine showed a dual mechanism of action, it binds to muscarinic and calcium receptors that can be related to its antispasmodic activity. The clinical trial has shown that pargeverine was an effective drug in the treatment of moderate to severe colic pain of biliary origin. In addition, its efficacy and tolerability were determined in patients with moderate-to-severe acute intestinal colic pain. As a result, no differences in blood pressure or heart rate were found among treatments. The incidence of mouth dryness was significantly more frequent with the 20 mg and 30 mg doses of propinox than with the placebo or the 10 mg dose. Information about the current development of this drug is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Lurosetron (GR 87442) is a serotonin 5HT3 receptor antagonist. It was undergoing clinical evaluation with Glaxo Wellcome in the UK as a potential drug for the treatment of emesis.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
ARMGO and Servier are developing an anti-arrhythmia drug aladorian (ARM036) for the treatment of heart failure, arrhythmia and ventricular tachycardia. Aladorian was the first in-house discovered, novel, small molecule NCE (Rycal®) from ARMGO’s library that was advanced into clinical studies. ARM036 completed multiple Phase IIa clinical studies in chronic heart failure patients, demonstrating positive activity and safety in patients, and validating ARMGO’s approach for drug discovery and candidate selection on the RyR target.
Status:
Investigational
Source:
NCT00427349: Phase 2 Interventional Completed Gastrointestinal Carcinoid Tumor
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Motesanib (AMG 706), a novel nicotinamide, was identified as a potent, orally bioavailable inhibitor of the VEGFR1/Flt1, VEGFR2/kinase domain receptor/Flk-1, VEGFR3/Flt4 and Kit receptors. Motesanib was expected to reduce vascular permeability and blood flow in human tumours. A phase III trial of motesanib in combination with paclitaxel and carboplatin in non-squamous NSCLC has been terminated by Takeda and subsequently the development was discontinued. Motesanib has also been investigated up to phase II in breast, thyroid, colorectal and gastrointestinal stromal tumours. However, development has been discontinued in these indications.
Status:
Investigational
Source:
INN:talaglumetad [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Talaglumetad (also known as LY-544344) is a bicyclohexane derivative patented by Eli Lilly and Company as modulators of metabotropic glutamate receptor. Talaglumetad acts as a prodrug of Eglumegad, a selective agonist of metabotropic glutamate receptors (mGluR2/3) and metabolized to release active compound by both human jejunal homogenates and rat liver homogenates. In experiments on mice, Talaglumetad was found to be as effective as diazepam for treating anxiety symptoms in several standard tests, but without producing any of the negative side effects of diazepam such as sedation and memory impairment.
Status:
Investigational
Source:
INN:delequamine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Delequamine is a selective antagonist of alpha2 adrenoreceptor, developed by Syntex Research. The compound was investigated for the treatment of erectile dysfunction and was modestly effective in younger (less than 45 years) subjects.
Status:
Investigational
Source:
NCT01094821: Phase 1/Phase 2 Interventional Completed Healthy
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Naronapride (ATI-7505), an orally administered, cisapride analogue and serotonin4 (5HT4) receptor agonist, is being developed by Renexxion for the treatment of multiple gastrointestinal disorders. Sinovant is initially developing naronapride for the treatment of irritable bowel syndrome – constipation (IBS-C), a disease that affects millions of Chinese patients and for which few effective treatment options are available. Naronapride has been evaluated in over 900 subjects in multiple randomized controlled clinical studies and has demonstrated promising results in patients with gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and chronic idiopathic constipation (CIC). Naronapride’s low systemic absorption and high specificity for 5HT4 and D2 receptors is thought to improve its safety and tolerability profile relative to other members of the class.
